A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults

S
Samir Gupta, MD

Primary Investigator

Overview

This trial will study putative therapeutics in a hospitalized population with moderate to severe COVID-19.

Description

Participants will be randomly assigned to receive placebo or an experimental study drug.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    COVID-19
  • Age: Between 18 Years - 100 Years
  • Gender: All

Individuals at least 18 years of age admitted to the hospital with symptoms suggestive of COVID-19.

Women who are pregnant or breastfeeding will not be eligible.

Updated on 20 Nov 2022. Study ID: 2005800939

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center